Outlook Therapeutics

News

Downward market trajectory in black bar chart

Outlook blindsided as FDA blocks wet AMD drug once again

Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.

News

NICE backs first ophthalmic bevacizumab for NHS use

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m

News

Outlook slumps as FDA rejects eye disease drug

Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege

Outlook blindsided as FDA blocks wet AMD drug once again

NICE backs first ophthalmic bevacizumab for NHS use

Outlook slumps as FDA rejects eye disease drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks